Eirgen Pharma Announces Strategic Executive Appointments to Support Ongoing Growth

Jan Willem Blüm, Chief Financial Officer James Murphy, Chief Operating Officer

Waterford, Ireland., April 29 2026 – Eirgen Pharma today appointment of two of its senior leaders to newly defined executive roles, reinforcing the company’s leadership structure as it continues to scale its global operations and manufacturing capabilities.

The appointments of James Murphy as Chief Operating Officer, and Jan Willem (JW) Blüm as Chief Finance Officer reflect Eirgen’s commitment to internal leadership development and the strengthening of governance frameworks required to support its evolving operational footprint.

James Murphy, Chief Operating Officer

Since joining Eirgen in 2021 as Head of Engineering, James has been instrumental in the expansion of the company’s high-potency development and commercial manufacturing infrastructure. With over 20 years of experience across research, product development, and manufacturing engineering, James is uniquely positioned to lead Eirgen’s operational future. In his new role, he will oversee Manufacturing, Packaging, Supply Chain, Business Development, Engineering, Facilities, EHS, and Operational Excellence, ensuring continued stability and coordinated performance across all production and development activities.

Jan Willem Blüm, Chief Financial Officer

Jan Willem (JW) joined Eirgen in 2021 as Head of Finance, brings over 19 years of extensive international leadership experience, with a background spanning financial planning, logistics, IT, and marketing across several European markets.  As CFO, he will oversee Financial Strategy and Governance, IT, HR, Learning & Development, and Legal. Jan Willem’s focus will be to ensure Eirgen’s organizational systems, financial planning, and cross-functional processes effectively align the company’s human capital and financial investments with its long-term strategic objectives.

“These appointments are a vital step in our maturation as an organization”, said Damien Burke CEO. “By elevating leaders who have been integral to our recent successes, we are ensuring both continuity and heightened focus on our operational and financial discipline necessary to navigate our next phase of growth.”

These strategic positions provide a stable foundation as Eirgen continues to expand its global reach and invest in its people, facilities, and technical capabilities to meet the increasing demand for specialized pharmaceutical services.

---

For more information about Eirgen Pharma and its mission to improve patients' lives worldwide, visit https://www.eirgen.com

Media Contact: Heather McGrath, heather.mcgrath@eirgen.com